 Antithrombotic effects novel stable prostacyclin analog stable prostacyclin analog alpha prostacyclin derivatives Iloprost prostaglandin derivative respect ADP-induced vitro aggregation human platelets vivo platelet aggregation rats dogs bolus injection i.v infusion compounds systemic arterial blood pressure rats dogs potent inhibitor vitro platelet aggregation ADP nM compounds report ex vivo effectiveness doses compounds active oral doses micrograms/kg new compound dose-dependent inhibition ex platelet aggregation rats compounds effective micrograms/kg addition definite antithrombotic effects dose range microgram/kg i.v various thrombosis models platelet aggregation involved results therapeutic potential thrombotic diseases